Precision medicine

#Europe #European Union #Precision medicine

EU backs Swiss Rockets Serbia precision medicine hub

Biotech company Swiss Rockets Serbia has signed a Joint Declaration of Intent with the European Commission (DG ENEST) and the Development Agency of Serbia (RAS) to establish a regional centre of excellence for precision medicine.  The joint declaration announces the ambition of Swiss Rockets Serbia, a subsidiary of Swiss Rockets… Read More

#Business & Investment #News

Protein degradation
#Frontier Medicines #Oncology #Precision medicine #Protein degradation

Study identifies new E3 ligase for targeted protein degradation

A new study in Structure, a Cell Press journal demonstrates that DCAF2 can be harnessed as a novel E3 ligase for targeted protein degradation (TPD).   The authors say DCAF2 presents an exciting opportunity to deliver tumour-targeted protein degraders given its frequent overexpression in various types… Read More

#Cancer Research #News

Test for KRAS mutation
#Bayer #KRAS #Kumquat Biosciences #Oncology #Precision medicine

Bayer and Kumquat collaborate on precision oncology

Bayer and Kumquat Biosciences have entered into an exclusive global license and collaboration agreement to develop and commercialise Kumquat’s KRAS G12D inhibitor.   Under the agreement, Kumquat is responsible for the initiation and completion of the Phase Ia study, while Bayer will complete development and commercial activities.  Kumquat received US Food… Read More

#Business & Investment #Cancer Research #News

Cancer research
#ASCO #Cancer immunotherapy #Cancer research #Cell therapy #Oncology #Precision medicine #Therapeutics

Expert commentary from ASCO 2025

This year’s American Society of Clinical Oncology (ASCO) Annual Meeting took place at the McCormick Place Convention Center in Chicago from 30 May to 3 June 2025. DDW’s Megan Thomas collected commentary from industry experts in attendance. CCR8 therapies gain clinical significance Stephan Schann is Chief Scientific Officer at Domain… Read More

#Cancer Research #Exclusive Content

#AI / data analytics / healthtech / informatics #Alzheimer's #CNS #Gene editing #Human disease models #Interview #Neurodegenerative disorders #Neurology #Neuropsychiatric disorders #Neuroscience #Precision medicine #PrecisionLife #Stem cells

Podcast: Unlocking neuroscience drug discovery

This is the latest episode of the free DDW narrated podcast, titled “Innovative uses for biomarkers in drug discovery”, which covers three articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “Advances in neuroscience drug discovery”, “Putting human data at the centre of… Read More

#News

#Bioinformatics #Enedra Therapeutics #Funding #Oncology #Precision medicine #Start-ups

Enedra secures financing for precision cancer therapies

Enedra Therapeutics has secured venture financing and non-dilutive funding through UKRI’s Innovate UK Future Economy Investor Partnerships programme to support the development of next-generation precision therapies for advanced, genetically heterogeneous cancers.  The financing round was supported by KU Leuven’s Centre for Drug Design and Discovery (CD3), o2h Ventures, and follow-on… Read More

#Business & Investment #News #Start-up Zone

AI brain
#Artificial intelligence (AI) #Drug discovery #Partnership #Precision medicine

Sonrai partners with Paige to improve AI drug discovery

AI precision medicine company Sonrai Analytics has announced a strategic partnership with AI company Paige designed to improve access to AI capabilities for precision medicine research and development. The partnership will see the integration of Paige’s foundation models with Sonrai’s cloud-based data analytics and bioinformatics platform to make AI, machine… Read More

#Business & Investment #News

#Biotherapeutics #DNA #Drug discovery #Gut microbiome #Microbiome #Precision medicine #Synthetic biology #Synthetic DNA

Podcast: How is precision medicine making its mark in drug discovery?

This is the latest episode of the free DDW narrated podcast, titled “How is precision medicine making its mark in drug discovery?”, which covers two articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “Accelerating biotherapy and personalised medicine with long DNA”… Read More

#News

#Gender #Neuroscience #Precision medicine #Women’s Brain Foundation

The urgent need for sex and gender to be recognised in drug discovery

DDW Editor Reece Armstrong speaks to Dr Antonella Santuccione Chadha, CEO of the Women’s Brain Foundation (WBF) about the importance of sex and gender differences in drug discovery efforts. The topic of gender disparity is a prevailing issue in modern society and is something which has caused fierce debate across political… Read More

#Exclusive Content

Cancer cells
#Cancer research #CAR-T #Gene mutation #Genetics / genomics #Immunotherapy #Interview #Mass spectrometry / NMR #Meet the Researcher #Nautilus #Oncology #Precision medicine #Protein chemistry / Proteomics #Rare cancers

Podcast: New ways of looking at effective cancer treatment

This is the latest episode of the free DDW narrated podcast, titled “New ways of looking at effective cancer treatment”, which covers three articles written for DDW Volume 24 – Issue 2, Spring 2023 of DDW. They are called: “3D Genomics and targeted cancer therapies”, “Democratising… Read More

#News

#Brain cancer #Genetic profiling #Machine learning #Oncology #Precision medicine #UCLA

ML study identifies new glioblastoma treatment strategy

A new precision medicine approach that combines genetic and functional profiling could predict how glioblastoma will respond to therapy.  A new study from scientists at the UCLA Health Jonsson Comprehensive Cancer Center helps explain why glioblastoma becomes resistant to treatment and introduces a new approach that paves… Read More

#Cancer Research #Editor's Choice #News

#Cancer drug targets #Genetics / genomics #Oncology #Precision medicine #Synthetic lethality

The promise of synthetic lethality in precision oncology

Kathryn L Chapman, Head of Discovery Biology & Jürgen Moll CSO at Tesselate Bio, explore alternative approaches to synthetic lethality to target cancer cells that use alternative lengthening of telomersin. Synthetic lethality and targeted drugs are a clinically established approach Synthetic lethality (SL) is an established, clinical and commercial approach… Read More

#Cancer Research #Exclusive Content

Neuron
#Neurology #Neuroscience #Precision medicine #Psychiatry #Webinar

Watch now! DDW Neuroscience Showcase

In this free online event hosted by DDW and co-sponsored by ApconiX and AxoSim, leading industry figures outline the areas of opportunity and challenges in the neuroscience drug discovery & development sector. The showcase includes a panel discussion looking at the use of new drug discovery… Read More

#News

Kidneys
#AstraZeneca #Clinical trials #Kidney disease #Precision medicine #RNA

AstraZeneca comment on precision medicine for kidney disease 

Regina Fritsche Danielson, Senior Vice President and Global Head, Research and Early Development, CVRM, AstraZeneca, shares insight with DDW’s Megan Thomas on the first precision medicine to treat APOL1-mediated kidney disease (AKMD). MT: Can you provide an overview of the key findings from the study on APOL1-mediated kidney disease (AKMD)? … Read More

#Exclusive Content

Drug discovery innovation
#AAV #Cell and gene therapy #Drug development #Drug discovery #Gene therapy #Genetics / genomics #Immunology / Virology & Vaccines #Interview #Life sciences #Market reporting #Precision medicine #RNA #RNA sequencing #Scandinavia #Sweden #Transcriptomics

Podcast: Innovation drivers and opportunities for drug discovery

This is the latest episode of the free DDW narrated podcast, titled “Innovation drivers and opportunities for drug discovery”, which covers three articles written Volume 24 – Issue 1, Winter 2022/2023 of DDW. They are called: Optimising AAV capsid purification through improved analytics How… Read More

#News